ClinicalTrials.gg
WithdrawnNCT07559448PEACE-CPUpdated Nov 19, 2026

Palatable Elemental Diet for Gastrointestinal Symptoms in Chronic Pancreatitis

An interventional study of Palatable Elemental Diet in Chronic Pancreatitis, sponsored by Stanford University. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Study withdrawn prior to participant enrollment because funding was not available to initiate the study.
Updated Nov 19, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Pancreatitis, Chronic with a site in United States — 27 open to participants now, 38 under way, none of them phase 3. Pancreatitis, Chronic · United States.

Enrollment
67th of 73
0 · median 32
Started
2026
with 7 others
No phase
32 of 111
8 open now
Registered
108th of 111
by date

Among the 111 studies in Pancreatitis, Chronic with a site in United States, this one is the 67th largest by enrollment of the 73 interventional ones that give a count, is one of 8 that started in 2026, is one of 32 with no phase, and was the 108th registered.

Pancreatitis, Chronic

266 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.

Browse Pancreatitis, Chronic studies →

Open to participants now

27 of the 111 studies in Pancreatitis, Chronic with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Pancreatitis, Chronic studies recruiting now, 31 (63%) set no upper age limit and 12 (24%) stop at 75 or younger; 8 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Pancreatitis, Chronic with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether a 2-week exclusive palatable elemental diet is feasible, tolerable, and acceptable for adults with chronic pancreatitis and bothersome gastrointestinal symptoms. An elemental diet is a nutritionally complete formula made from ingredients that are easy to absorb. The main questions it aims to answer are whether participants can complete the diet as planned, and whether they can take in most of the prescribed formula, and how acceptable the study diet is to participants at the end of the 2-week diet period.

03

Conditions studied

  • Chronic Pancreatitis

Keywords

  • chronic pancreatitis
  • elemental diet
  • palatable elemental diet
  • gastrointestinal symptoms
  • abdominal pain
  • microbiome
  • feasibility study
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 75 years
  • Clinical diagnosis of chronic pancreatitis based on medical history and study physician assessment
  • Self-reported chronic pancreatitis-related gastrointestinal symptoms within 30 days before enrollment, with significant global gastrointestinal symptom burden defined as a Structured Assessment of Gastrointestinal Symptoms (SAGIS) score of 16 or higher

Exclusion criteria

Exclusion Criteria:

  • Pancreatic tumor or pancreatic cancer
  • History of pancreatic surgery
  • Pregnancy or breastfeeding
  • Diagnosis of a condition other than chronic pancreatitis that contributes to gastrointestinal symptoms, based on medical history or study physician assessment
  • Active infection or antibiotic use within the last month
  • History of phenylketonuria
  • Insulin-dependent diabetes or diabetes requiring insulin treatment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Palatable Elemental Diet

    Participants in this single-arm study will consume an exclusive oral palatable elemental diet for 14 days. During the intervention period, participants will complete daily diet and symptom diaries and undergo study assessments, including questionnaires and biospecimen collection. After the 14-day diet period, participants will resume their usual diet and continue follow-up for 4 additional weeks.

    Other: Palatable Elemental Diet

Interventions

  • OtherPalatable Elemental Diet

    The intervention is an exclusive oral palatable elemental diet administered for 14 consecutive days as the participant's sole nutritional intake. This amino acid-based formula was developed to provide an elemental diet with improved palatability and tolerability. Following completion of the 14-day diet period, participants will return to their usual diet and undergo 4 additional weeks of follow-up.

    Also known as: Elemental Diet, Exclusive Oral Palatable Elemental Diet

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Complete at Least 12 of 14 Days of the Palatable Elemental Diet

    Completion is defined as completing at least 12 of the 14 study diet days during the exclusive palatable elemental diet period. The feasibility target is that at least 80% of participants meet this criterion.

    Time frame: During the 14-day exclusive palatable elemental diet period (Day 14 to Day 28)

  2. Number of Participants Who Consume at Least 75% of Prescribed Palatable Elemental Diet Calories

    Diet adherence is defined as consuming at least 75% of prescribed palatable elemental diet calories during the 14-day exclusive diet period, based on daily diary tracking. The feasibility target is that at least 75% of participants meet this criterion.

    Time frame: During the 14-day exclusive palatable elemental diet period (Day 14 to Day 28)

Secondary outcomes

  1. Participant-Reported Acceptability of the Palatable Elemental Diet

    Acceptability will be assessed using participant-reported questionnaire items completed at Day 28. Items will assess organoleptic acceptability of the study diet, including appearance, smell, taste, aftertaste, and consistency, as well as overall acceptability. Responses will be summarized descriptively.

    Time frame: Day 28, after completion of the 14-day exclusive palatable elemental diet period

  2. Change From Baseline in Structured Assessment of Gastrointestinal Symptoms Global Symptom Burden Score

    Structured Assessment of Gastrointestinal Symptoms total score. The instrument uses 22 Likert-scale questions to calculate total gastrointestinal symptom burden, with a total score range of 0 to 88. Higher scores indicate worse gastrointestinal symptom burden.

    Time frame: Baseline, Day 28, and Day 56

  3. Change From Baseline in Patient-Reported Outcomes Measurement Information System Global Health Version 1.2 (PROMIS Global Health v1.2) Summary Score

    PROMIS Global Health v1.2 summary score derived from the 10-item questionnaire administered at study visits. The instrument assesses general, physical, mental, and social health, including physical function, emotional problems, fatigue, and pain. Nine items use 5-point response scales and 1 pain item uses a 0-to-10 scale. Higher scores indicate better global health overall.

    Time frame: Baseline, Day 28, and Day 56

07

Study locations

1 site
  • Stanford Digestive Health Care Center
    Redwood City, California 94063, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Jul 2028, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 30, 2026
StartEst.
Aug 2026
Primary completionEst.
Jul 2028
CompletionEst.
Aug 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Study withdrawn prior to participant enrollment because funding was not available to initiate the study.
changed Nov 19, 2026
Enrollment
15 (estimated)→0 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Withdrawn
    Why stopped Study withdrawn prior to participant enrollment because funding was not available to initiate the study.
    Enrollment 15 (estimated)→0 (actual)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07559448
Collaborators
Cedars-Sinai Medical Center, mBIOTA
Responsible party
Yi Jiang (Assistant Clinical Professor, Stanford University) — Principal investigator
First posted
Apr 30, 2026
Start date
Aug 2026 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Yi Jiang, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion